SCHEMBL5068892

SCHEMBL5068892

CSc1ncnc2sc(-c3ccc(CN(CCO)C(=O)OC(C)(C)C)cc3)nc12

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SSTR4 P31391 1/20 0.40
PAX8 Q06710 1/20 0.35
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
CCNE2 O96020 1/20 0.32
CCNE1 P24864 1/20 0.32
CDK2 P24941 1/20 0.32
HTT P42858 1/20 0.31
AGTR1 P30556 1/20 0.30
AGTR2 P50052 1/20 0.30
GRM2 Q14416 1/20 0.30
PIK3CD O00329 1/20 0.30
PIK3CA P42336 1/20 0.30
PIK3CB P42338 1/20 0.30
PIK3CG P48736 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5069029 0.92 PAX8 (0.34) SSTR4PAX8HDAC3HDAC1HDAC2
SCHEMBL5068866 0.91 PAX8 (0.34) SSTR4PAX8HDAC3HDAC1HDAC2
SCHEMBL5061163 0.91 SSTR4 (0.37) SSTR4PAX8HDAC1CDK2HTT
SCHEMBL5064760 0.90 PAX8 (0.33) SSTR4PAX8HDAC3HDAC1HDAC2
SCHEMBL5067502 0.89 IKBKB (0.38) SSTR4PAX8HDAC3HDAC1HDAC2
SCHEMBL5064178 0.81 IKBKB (0.34) PAX8HDAC3HDAC1HDAC2NCOR2
SCHEMBL14032002 0.80 PPARA (0.34) PAX8CDK2HTT
SCHEMBL30577132 0.70 SSTR4 (0.48) SSTR4HDAC3HDAC1HDAC2NCOR2
SCHEMBL13547362 0.70 SSTR4 (0.49) SSTR4HDAC3HDAC1HDAC2NCOR2
SCHEMBL14002386 0.69 SSTR4 (0.51) SSTR4HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 SSTR4 432/4885PAX8 2373/4885HDAC3 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.